Skip to Content

'
Khandan Keyomarsi, Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Hubert L. and Olive Stringer Professorship in Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Graduate School in Biomedical Sciences, The University of Texas, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 66
Houston, TX 77030
Room Number: Y3.5314a
Phone: (713) 792-4845
Fax: (713) 794-5369
Email: kkeyomar@mdanderson.org

Education & Training

Degree-Granting Education

1993 Harvard Medical School, Boston, MA, Post-doc, BCMP
1989 University of Southern California, Los Angeles, CA, PHD, Biochemistry
1983 University of California at Santa Barbara, Santa Barbara, CA, BA, Pharmacology

Postgraduate Training

1989-1993 Postdoctoral Fellow, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, (Arthur B. Pardee)

Experience/Service

Academic Appointments

Professor with Commendation, Graduate School of Biomedical Sciences, The University of Texas, Houston, TX, 2009

Honors and Awards

2009-present Hubert L. and Olive Stringer Professorship in Medical Oncology
2002 Faculty Scholar Award, MD Anderson Cancer Center

Selected Publications

Peer-Reviewed Original Research Articles
1. Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle 11(7):1468-76, 4/2012. e-Pub 4/2012. PMCID: PMC3350882.
2. Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat 132(2):575-88, 4/2012. e-Pub 6/2011. PMID: 21695458.
3. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet 8(3):e1002538, 3/2012. e-Pub 3/2012. PMCID: PMC3315462.
4. Valero V, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Ther 18(7):510-9, 7/2011. e-Pub 5/2011. PMID: 21546925.
5. Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K. Cdk2 is required for breast cancer mediated by the low molecular weight isoform of cyclin E. Cancer Res 71(9):3377-86, 5/2011. e-Pub 3/2011. PMCID: PMC3085722.
6. Keyomarsi K, Efuet ET, Bui TN. Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. Cell Biol Toxicol 27(2):123-31, 4/2011. e-Pub 9/2010. PMID: 20853140.
7. Caruso JA, Hunt KK, Keyomarsi K. The Neutrophil Elastase Inhibitor Elafin Triggers Rb-Mediated Growth Arrest and Caspase-Dependent Apoptosis in Breast Cancer. Cancer Res 70(18):7125-36, 9/2010. e-Pub 9/2010. PMCID: PMC2940941.
8. Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 29(27):3896-907, 7/2010. e-Pub 5/2010. PMCID: PMC2900397.
9. Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Res 70(12):5085-95, 6/2010. e-Pub 6/2010. PMCID: PMC2946214.
10. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 70(12):5074-84, 6/2010. e-Pub 6/2010. PMCID: PMC2888821.
11. Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle 9(6). e-Pub 3/2010. PMID: 20237430.
12. Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 16(4):1179-90, 2/15/2010. e-Pub 2/9/2010. PMCID: PMC2822889.
13. Mull BB, Cox J, Bui T, Keyomarsi K. Post-translational modification and stability of low molecular weight cyclin E. Oncogene 28(35):3167-76, 9/2009. e-Pub 6/2009. PMID: 19561641.
14. Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat 115(3):651-9, 6/2009. e-Pub 12/24/2008. PMID: 19107593.
15. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 15(11):3654-62, 6/2009. e-Pub 5/2009. PMID: 19470724.
16. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early onset breast cancer. PLoS Med 6(5):e1000068, e1000068, 5/2009. e-Pub 5/2009. PMCID: PMC2673042.
17. Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res 69(7):2817-25, 4/1/2009. e-Pub 3/24/2009. PMCID: PMC2669888.
18. Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle 8(7):1062-8, 4/1/2009. e-Pub 4/10/2009. PMCID: PMC2692060.
19. Keyomarsi K. A novel MCM-2 fragment with potential biological function in senescence. Cell Cycle 7(22):3480, 11/15/2008. e-Pub 11/15/2008. PMID: 19001846.
20. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68(19):7966-74, 10/2008. PMCID: PMC2561224.
21. Javanmoghadam-Kamrani S, Keyomarsi K. Synchronization of the cell cycle using lovastatin. Cell Cycle 7(15):2434-40, 8/2008. e-Pub 5/2008. PMID: 18677105.
22. Yokota T, Bui T, Liu Y, Yi M, Hunt KK, Keyomarsi K. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Res 67(23):11272-83, 12/2007. PMID: 18056453.
23. von Holzen U, Pataer A, Raju U, Bocangel D, Vorburger SA, Liu Y, Lu X, Roth JA, Aggarwal BB, Barber GN, Keyomarsi K, Hunt KK, Swisher SG. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Clin Cancer Res 13(20):6032-9, 10/2007. PMID: 17947465.
24. Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clin Cancer Res 13(16):4800-6, 8/2007. PMID: 17699858.
25. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67(15):7212-22, 8/2007. PMID: 17671189.
26. Lambert L, Keyomarsi K. Cell cycle deregulation in breast cancer: insurmountable chemoresistance or Achilles' heel? Adv Exp Med Biol 608:52-69, 2007. PMID: 17993232.
27. Barton MC, Akli S, Keyomarsi K. Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer. J Cell Physiol 209(3):686-94, 12/2006. PMID: 17001684.
28. McGahren-Murray M, Terry NH, Keyomarsi K. The Differential Staurosporine-Mediated G1 Arrest in Normal versus Tumor Cells Is Dependent on the Retinoblastoma Protein. Cancer Res 66(19):9744-53, 10/2006. PMID: 17018634.
29. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC, Jr. Anti-HER2 Antibody Trastuzumab Inhibits CDK2-Mediated NPAT and Histone H4 Expression via the PI3K Pathway. Cell Cycle 5(15):1654-61, 8/2006. PMID: 16861913.
30. Efuet ET, Keyomarsi K. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res 66(2):1040-51, 1/15/2006. PMID: 16424040.
31. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102(35):12519-24, 8/2005. PMID: 16116079.
32. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280(15):15148-57, 4/2005. PMID: 15708847.
33. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, Reed JA, Timchenko N, van den Oord JJ, Bar-Eli M, Keyomarsi K, Medrano EE. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 65(3):692-7, 2/2005. PMID: 15705861.

Grant & Contract Support

Title: Evaluating pharmacological inhibition of neutrophil elastase as an anti-tumor strategy against breast cancer
Funding Source: Dainippon Sumitomo Pharma Co., Ltd
Role: Principal Investigator-MDACC
Duration: 10/12/2012 - 10/11/2014
 
Title: Angela Alexander, DOD Breast Cancer Postdoctoral Fellowship Award, Establishing cyclin E/CDK2 as a novel therapeutic target in inflammatory breast cancer
Funding Source: Department of Defense (DOD)
Role: Mentor of PI
Duration: 9/20/2012 - 9/30/2013
 
Title: Multidicsplinary Subspecialty Pathology Research Fellowship Program
Funding Source: NIH/NCI
Role: Multi-Investigator
Principal Investigator: Bogdan Czerniak, Khandan Keyomarsi, Aysegul Sahin
Duration: 9/23/2011 - 8/31/2016
 
Title: Lonestar Oncology Network for Epigenetics, Therapy and Research: Breast Cancer Cell Resource Core Facility C:1 Tissue Culture
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Core Leader
Principal Investigator: Sharon Dent
Duration: 6/1/2011 - 5/31/2016
 
Title: Targeting the cell cycle in triple negative breast cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2011 - 3/30/2016
 
Title: Proteolytic Processing of Cyclin E in Breast Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 12/17/2010 - 11/30/2015
 
Title: The Future of Cancer Research: Training Program for Basic and Translational Scientists
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator
Principal Investigator: Raymond DuBois
Duration: 9/1/2010 - 8/31/2013
 
Title: LMW-E, A Novel Indicator of Letrozole Resistance in Breast Cancer
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 8/1/2010 - 7/31/2013
 
Title: CDK2 is a Novel Target for Triple Negative Breast Cancer
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Investigator
Principal Investigator: Kelly Hunt
Duration: 8/1/2010 - 7/31/2013
 
Title: Kimberly Szymanski, Department of Defense Breast Cancer Research Program
Funding Source: Department of Defense (DOD)
Role: Mentor of PI
Duration: 6/1/2010 - 5/31/2013
 
Title: Natalie Jabbour, Autophagy as a therapeutic target against triple negative breast cancer
Funding Source: NIH CCTS T32 Fellowship (UT Health Science Center Houston)
Role: Mentor of GSBS student and PI
Principal Investigator: Natalie Jabbour
Duration: 4/1/2010 - 3/31/2013
 
Title: Joseph A. Caruso, Isaiah J. Fidler Graduate Fellowship in Cancer Metastasis, UT MD Anderson Cancer Center, Graduate Program in Cancer Metastasis Researach: From Bench to Bedside
Funding Source: UT MD Anderson Cancer Center
Role: Mentor of PI
Principal Investigator: Joseph A. Caruso
Duration: 2/1/2010 - 1/31/2013
 
Title: MyLinh Duong, Cell cycle deregulation by LMW cyclin E and p53 disrupts mammary acinar morphogenesis. Department of Defense
Funding Source: Department of Defense (DOD)
Role: Mentor of PI
Principal Investigator: MyLinh Duong
Duration: 11/1/2008 - 10/31/2011
 
Title: Elizabeth Mittendorf, Cyclin E: Implications for targeted therapy in Her2-overexpressing breast cancer
Funding Source: NIH/NCI
Role: Mentor of PI
Principal Investigator: Elizabeth Mittendorf
Duration: 8/1/2008 - 7/30/2013
 
Title: Cancer Center Support (Core) Grant - Breast Cancer Program
Funding Source: DHHS - NIH-NCI
Role: Co-Principal Investigator
Principal Investigator: Ronald DePinho
Duration: 7/1/2008 - 6/30/2013
 
Title: Nikki Delk, Mechanistic regulation of the tumor specific forms of cyclin E in breast cancer
Funding Source: NIH/NCI
Role: Mentor of PI
Principal Investigator: Nikki Delk
Duration: 6/1/2008 - 5/31/2011
 
Title: Anna Biernacka, Susan G. Komen for the Cure, HER2 and Cyclin E: Novel interaction and opportunities for therapy
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Mentor of PI
Principal Investigator: Anna Biernacka
Duration: 11/14/2007 - 11/13/2010
 
Title: Elizabeth Mittendorf, Her2 regulation of low molecular weight cyclin E isoforms in breast cancer, American Association for Cancer Researach-Genentech BioOncology Fellowship for Cancer Research on the Her Family Pathway
Funding Source: American Association for Cancer Research (AACR)
Role: Mentor of PI
Principal Investigator: Elizabeth Mittendorf
Duration: 7/1/2007 - 6/30/2009
 
Title: PHD training for predoctoral fellows in the area of Clinical and Translational Science
Funding Source: NIH
Role: Collaborator
Principal Investigator: David McPherson
Duration: 9/30/2006 - 6/30/2011
 
Title: Sonia Kamrani, Cell cycle regulation of ER alpha in breast cancer, US Department of Defense
Funding Source: Department of Defense (DOD)
Role: Mentor of PI
Principal Investigator: Sonia Kamrani
Duration: 3/1/2006 - 3/31/2009
 
Title: Cyclin E as a Novel and Powerful Prognosticator for Breast Cancer
Funding Source: NIH/NCI
Role: Project 2 SPORE Principal Investigator
Principal Investigator: Hortobagyi
Duration: 7/1/2005 - 8/31/2011
 
Title: Tomoya Yokota, Mechanism of elafin downregulation in breast cancer cells
Funding Source: MDACC Odyssey Fellowship
Role: Mentor of PI
Principal Investigator: Tomoya Yokota
Duration: 6/1/2005 - 5/31/2008
 
Title: Benjamin Mull, Specific reversible cytostatic protection of normal cells against chemotherapeutics in breast cancer therapy, US Department of Defense
Funding Source: Department of Defense (DOD)
Role: Mentor of PI
Principal Investigator: Benjamin Mull
Duration: 2/21/2005 - 3/20/2008
 
Title: Ekem Efuet, Novel Mechanism of interaction of statins with the proteasome: implications in breast cancer
Funding Source: NIH/NCI
Role: Mentor of PI
Principal Investigator: Ekem Efuet
Duration: 5/1/2001 - 4/30/2010

Last updated: 3/1/2013